HH-2853 is a potent and selective dual EZH1/2 inhibitor with low nM IC50 values. It effectively reduces H3K27 methylation in cells and shows superior in vivo antitumor efficacy compared to tazemetostat in xenograft models with EZH2 mutations or SWI/SNF alterations, making it a valuable research tool for epigenetics and oncology studies.
Molekulargewicht:
611.66
CAS Nummer:
[2202678-04-2]
Formel:
C31H36F3N7O3
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten